These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 8808645

  • 1. Synergism of IL-2-stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro.
    Eslami Z, Gaucher D, Tanner CE.
    Clin Immunol Immunopathol; 1996 Oct; 81(1):74-81. PubMed ID: 8808645
    [Abstract] [Full Text] [Related]

  • 2. IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo.
    Olivier M, Eslami Z, Tanner CE.
    J Parasitol; 1996 Feb; 82(1):78-81. PubMed ID: 8627506
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy with IL-2-stimulated splenocytes reduces in vitro the level of Leishmania donovani infection in peritoneal macrophages.
    Eslami Z, Olivier M, Tanner CE.
    Int J Parasitol; 1995 Aug; 25(8):975-81. PubMed ID: 8550297
    [Abstract] [Full Text] [Related]

  • 4. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.
    Haldar AK, Banerjee S, Naskar K, Kalita D, Islam NS, Roy S.
    Exp Parasitol; 2009 Jun; 122(2):145-54. PubMed ID: 19422069
    [Abstract] [Full Text] [Related]

  • 5. rIL-2-stimulated splenocytes reactivate the NO2-producing ability of macrophages infected by Leishmania donovani.
    Eslami Z, Tanner CE.
    Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):465-87. PubMed ID: 10946826
    [Abstract] [Full Text] [Related]

  • 6. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S, Sinha S, Singh SK, Narayan S, Kumar V, Verma N, Ranjan A, Sinha PK, Das VN, Pandey K, Kar SK, Das P.
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [Abstract] [Full Text] [Related]

  • 7. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
    Banduwardene R, Mullen AB, Carter KC.
    Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
    [Abstract] [Full Text] [Related]

  • 8. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P, Parmar N, Yadav PK, Chandrakar P, Kar S.
    J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
    [Abstract] [Full Text] [Related]

  • 9. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony.
    Murray HW, Berman JD, Wright SD.
    J Infect Dis; 1988 May; 157(5):973-8. PubMed ID: 2834469
    [Abstract] [Full Text] [Related]

  • 10. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S, Ghosh P, De T, Gomes A, Gomes A, Dungdung SR.
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [Abstract] [Full Text] [Related]

  • 11. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB, Lawrence CE, McFarlane E, Wei XQ, Carter KC.
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [Abstract] [Full Text] [Related]

  • 12. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H, Hockertz S.
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [Abstract] [Full Text] [Related]

  • 13. The leishmanicidal activity of oleuropein is selectively regulated through inflammation- and oxidative stress-related genes.
    Kyriazis ID, Koutsoni OS, Aligiannis N, Karampetsou K, Skaltsounis AL, Dotsika E.
    Parasit Vectors; 2016 Aug 09; 9(1):441. PubMed ID: 27501956
    [Abstract] [Full Text] [Related]

  • 14. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC, Mullen AB, Sundar S, Kenney RT.
    Antimicrob Agents Chemother; 2001 Dec 09; 45(12):3555-9. PubMed ID: 11709339
    [Abstract] [Full Text] [Related]

  • 15. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.
    Murray HW, Xiang Z, Ma X.
    Am J Trop Med Hyg; 2006 Jun 09; 74(6):1013-5. PubMed ID: 16760512
    [Abstract] [Full Text] [Related]

  • 16. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
    Carter KC, Baillie AJ, Mullen AB.
    Clin Diagn Lab Immunol; 1999 Jan 09; 6(1):61-5. PubMed ID: 9874665
    [Abstract] [Full Text] [Related]

  • 17. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.
    Murray HW, Oca MJ, Granger AM, Schreiber RD.
    J Clin Invest; 1989 Apr 09; 83(4):1253-7. PubMed ID: 2539396
    [Abstract] [Full Text] [Related]

  • 18. Antileishmanial drug targeting through glycosylated polymers specifically internalized by macrophage membrane lectins.
    Nègre E, Chance ML, Hanboula SY, Monsigny M, Roche AC, Mayer RM, Hommel M.
    Antimicrob Agents Chemother; 1992 Oct 09; 36(10):2228-32. PubMed ID: 1332591
    [Abstract] [Full Text] [Related]

  • 19. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
    Bhattacharjee A, Majumder S, Majumdar SB, Choudhuri SK, Roy S, Majumdar S.
    Int J Antimicrob Agents; 2015 Mar 09; 45(3):268-77. PubMed ID: 25600891
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis.
    Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S.
    J Immunol; 2003 Jun 01; 170(11):5625-9. PubMed ID: 12759442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.